Chemoradiotherapy in Elderly Patients With Oesophagus Cancer

Recruiting now · Phase 1/Phase 2

Conditions studied: Oesophagus Cancer, Elderly Patients

In brief

Management of elderly patient with cancer is a therapeutic challenge and a public health problem. The mean age of esophageal cancer is 64.5 years and 72.1 years in men and women respectively. Surgery is a standard treatment reserved to about 30 % of patients. The other 70 % are considered unfit for surgery for various reasons, including ageing. Chemoradiotherapy (CRT) is standard treatment for patients with esophageal cancer unfit for surgery. The validated treatment scheme is external beam radiotherapy (EBRT) 50 Gy over 5 weeks combined with cisplatin and 5FU infusion. However it induces high rates of severe and life threatening toxicities: grade 3 haematologic and esophageal mucositis of 20 and 25 % respectively, in patients with a median age of 64 years. CRT has not been properly evaluated in patients more than 75 years, and other combined chemotherapy are challenging.

Key facts

Study ID

NCT02735057

Run by

Centre Hospitalier Universitaire de Besancon

People needed

54

Starts

2016-04-04

Expected to finish

2029-05-16

Last updated by the study team

2024-01-18

Who can join

Age: 75 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Esophageal cancer, squamous and adenocarcinoma types, T1-3, N0-1, M1a (TNM 6th),
• age > 75 years,
• WHO status < 2, Balducci 1, adequate bone marrow reserve, normal renal and hepatic function.

You may not qualify if…

• age < 75 years

Where it is running

• Centre Hospitalier Universitaire de Besançon — Besançon, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.